Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivo

Figure 2

Effect of ENMD-1198 on signaling in HCC cells. Western blot analysis was performed to determine signaling pathways affected by therapy with ENMD-1198. Recombinant EGF (40 ng/ml) was used for stimulating cells after pre-incubation with ENMD-1198 (16 hours). A) HUH-7 cells and B) HepG2 cells were used for experiments. ENMD-1198 abrogated EGF-induced phosphorylation of Akt (HUH-7), FAK (HUH-7), p44/42 MAPK (HepG2), and STAT3 (HUH-7, HepG2). β-actin served as a loading control.

Back to article page